Combination Ranibizumab and Bromfenac for Neovascular Age-related Macular Degeneration
Part of paid clinical trials in Portland, Oregon.
- Sponsor
- Oregon Health and Science University
- Study ID
- NCT00805233
- Phase
- PHASE2
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 50 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- combination ranibizumab + bromfenac — DRUGranibizumab injection in study eye each month for 4 months then as needed each month for 8 months. Plus one drop of bromfenac in the study eye twice per day, each day, for 12 months.
- ranibizumab injection alone — DRUGranibizumab injection in study eye each month for 4 months then as needed each month for 8 months
Study Details
This open-label, randomized, Phase II research study will look to see whether an investigational treatment combining bromfenac ophthalmic drops with ranibizumab intravitreal injection is safe and effective for treating wet AMD as compared to ranibizumab alone.
Key Dates
- First listed
- Dec 9, 2008
- Start date
- Dec 31, 2008
- Status verified
- Oct 2009
- Primary completion
- Sep 30, 2010
- Completion
- Sep 30, 2010
Study Design
- Enrollment
- 30 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: 1Combination Ranibizumab intravitreal injection plus bromfenac ophthalmic drops
- Active Comparator: 2ranibizumab injection alone.
Primary Outcome Measure
Assessment of ocular adverse events, including uncontrolled inflammation, endophthalmitis, and retinal tear/detachment, abnormal sensation in eye, conjunctival hyperemia, eye irritation, eye pain, eye pruritus, eye redness, headache, and iritis [ Time Frame: monthly ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Casey Eye Institute at Oregon Health & Science University | Portland | Oregon | 97239 | - |
Find similar trials in Portland, OR
By condition
By specialty
Related Studies
- A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)PHASE2/PHASE3 · Recruiting · EyeBiotech Ltd. · Scottsdale, Arizona
- National Eye Institute Biorepository for Retinal DiseasesRecruiting · National Eye Institute (NEI) · Bethesda, Maryland
- High Resolution Retinal ImagingRecruiting · University of Pennsylvania · Philadelphia, Pennsylvania
- Stem Cell Ophthalmology Treatment Study IIRecruiting · MD Stem Cells · Westport, Connecticut